Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX)
(Real Time Quote from BATS)
$6.95 USD
+0.15 (2.21%)
Updated Aug 8, 2025 01:52 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Biodexa Pharmaceuticals PLC Unsponsored ADR's dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
BDRX 6.95 +0.15(2.21%)
Will BDRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BDRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BDRX
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock
BDRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
Are Medical Stocks Lagging Argenx (ARGX) This Year?
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Moves to Buy: Rationale Behind the Upgrade
Other News for BDRX
ADR Ratio Change Effective | BDRX Stock News
Biodexa Pharmaceuticals (BDRX) Trading Halted with Pending News
Biodexa Pharmaceuticals PLC-ADR trading halted, news pending
How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover ...
Biodexa Pharmaceuticals announces 1-for-10 reverse ADR split to regain Nasdaq compliance